Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Clinical Transplantation|July 16, 2017
Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantationKonstantinos Lontos, Mounzer Agha, Anastasios Raptis, et al.
Journal of Palliative Medicine|October 19, 2020
Primary Palliative Care for Patients with Advanced Hematologic Malignancies: A Pilot Trial of the SHARE InterventionJudith M Resick, Caroline Sefcik, Robert M Arnold, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 25, 2021
A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapyChristi McKeown, Asha Ricciuti, Mounzer Agha, et al.
Leukemia & Lymphoma|April 5, 2018
A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemiaRobert L Redner, Jan H Beumer, Patricia Kropf, et al.
Blood|October 27, 2023
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001Jeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Cytotherapy|September 3, 2017
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemiaMichael Boyiadzis, Mounzer Agha, Robert L Redner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host DiseaseMarie Bleakley, Alison Sehgal, Stuart Seropian, et al.
Blood and Lymphatic Cancer : Targets and Therapy|September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial TherapyChaitra Ujjani, Anthony Mato, Brian T Hill, et al.
Blood|June 4, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCLJeremy S Abramson, Tanya Siddiqi, Leo I Gordon, et al.
Lancet (London, England)|September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyJeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Pageof 3